Caribou Biosciences Reports Third Quarter 2026 Financial Results
Caribou Biosciences reported its financial results for the third quarter of 2026, highlighting a net loss of $26.6 million and ongoing strategic restructuring efforts.
Stocks · News reference
This Tyler Technologies Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Analysts downgraded STZ, TYL, DK, CRBU and PSX; price targets changed for STZ, TYL, DK and PSX.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Delek US Holdings Reports Third Quarter 2026 Results
Delek US Holdings, Inc. reported third-quarter 2026 financial results, exceeding analyst expectations for both revenue and adjusted earnings per share.
8-K filing — Delek US Holdings, Inc. (DK)
Filed: 2026-11-06 AccNo: 0001628280-26-071294 Size: 4 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Enbridge, Moderna On Deck Friday As Demand, Vaccine Pipeline Face Test
Enbridge headlines Friday’s reports, with investors weighing whether resilient pipeline utilization can offset a softer revenue comparison. Moderna, Brookfield Asset Management, Humana, Vistra, PPL, Plains All American
Caribou Biosciences Announces Acceptance of Clinical Abstracts for 2026 ASH Annual Meeting
Caribou Biosciences announced that clinical abstracts for its vispa-cel and CB-011 programs have been accepted for presentation at the 2026 American Society of Hematology (ASH) Annual Meeting.
Phillips 66 Appoints Chris Chandler as Executive Vice President and Strategic Advisor to the CEO
Phillips 66 has appointed Chris Chandler as Executive Vice President and Strategic Advisor to the CEO, leveraging his extensive experience in the energy industry.